Figure S2 from MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

A. Relative cytokine release observed after \ 24 hours from T cells in the presence of bispecific molecules (5 nM) and C4-2B target cells. Data plotted is within the limit of detection of the assay. B, C. Activation and cytokine release induced by the anti-PSMA x I2C ADAPTIR control molecule. PBMC were stimulated for 20 hrs in the presence of serial dilutions of C4-2B with tandem scFv-scFv (scFv-scFv), the hybrid ADAPTIR molecule or MOR209/ES414 as described before. B. Activation was assessed by measuring the fraction of CD4+ or CD8+ T cells upregulating CD69. C. Cytokine secretion was measured in the culture supernatants. The graphs show levels of IL-2, and IFN-γ; similar trends were observed for TNFα, GM-CSF, IL-4, IL-5 IL-10, IL-13 and IL-17. The figure shows representative results obtained from two independent experiments, each including 2 different human PBMC donors.